NVNBW
ENVVENO MED CORP
Price Chart
No historical data available
Latest Quote
$0.01
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 1,798 |
Stock Information
| Total Debt | $791K |
| Cash Equivalents | $30.95M |
| Net Income | $-21.96M |
| Exchange | PNK |
Recent Price History
About ENVVENO MED CORP
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
đ° Latest News
Insider Buyers Lose Additional US$294k As enVVeno Medical Dips To US$6.5m
Simply Wall St. âĸ 2025-11-22T12:30:44ZNVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
Zacks âĸ 2025-08-25T12:49:00ZEnVVeno Medical Gets FDA Not-Approvable Letter for VenoValve; Shares Fall 70%
MT Newswires âĸ 2025-08-20T15:57:09ZCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2025-06-26T15:31:55ZIncome Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $23,826,000 | $25,238,000 | $24,932,000 | $16,893,000 |
| Other Income Expense | $1,618,000 | $1,542,000 | $102,000 | $346,000 |
| Net Non Operating Interest Income Expense | $389,000 | $180,000 | $161,000 | $19,000 |
| Operating Expense | $23,826,000 | $25,238,000 | $24,932,000 | $16,893,000 |
| Other Non Operating Income Expenses | - | - | - | $33,000 |
| Total Other Finance Cost | - | - | - | $-18,709 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Net Interest Income | $389,000 | $180,000 | $161,000 | $19,000 |
| Interest Income | $389,000 | $180,000 | $161,000 | $19,000 |
| Normalized Income | $-23,437,000 | $-25,058,000 | $-24,771,000 | $-16,841,000 |
| Net Income From Continuing And Discontinued Operation | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Total Operating Income As Reported | $-23,826,000 | $-25,238,000 | $-24,932,000 | $-16,893,000 |
| Net Income Common Stockholders | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Net Income | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Net Income Including Noncontrolling Interests | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Net Income Continuous Operations | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Pretax Income | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Interest Income Non Operating | $389,000 | $180,000 | $161,000 | $19,000 |
| Operating Income | $-23,826,000 | $-25,238,000 | $-24,932,000 | $-16,893,000 |
| Special Income Charges | - | - | $0 | $313,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,916,000 | $-26,234,000 | $-24,509,000 | $-16,753,000 |
| Total Unusual Items | $1,618,000 | $1,542,000 | $102,000 | $313,000 |
| Total Unusual Items Excluding Goodwill | $1,618,000 | $1,542,000 | $102,000 | $313,000 |
| Reconciled Depreciation | $528,000 | $546,000 | $525,000 | $453,000 |
| EBITDA (Bullshit earnings) | $-23,298,000 | $-24,692,000 | $-24,407,000 | $-16,440,000 |
| EBIT | $-23,826,000 | $-25,238,000 | $-24,932,000 | $-16,893,000 |
| Diluted NI Availto Com Stockholders | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Gain On Sale Of Security | $1,618,000 | $1,542,000 | $102,000 | - |
| Research And Development | $12,249,000 | $13,583,000 | $9,914,000 | $5,728,000 |
| Selling General And Administration | $11,577,000 | $11,655,000 | $15,018,000 | $11,165,000 |
| Other Special Charges | - | - | - | $-313,000 |
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Total Assets | $44,954,000 | $48,635,000 | $41,661,000 | $57,699,000 |
| Total Non Current Assets | $1,220,000 | $1,712,000 | $2,225,000 | $2,659,000 |
| Non Current Prepaid Assets | $31,000 | $31,000 | $31,000 | $54,000 |
| Current Assets | $43,734,000 | $46,923,000 | $39,436,000 | $55,040,000 |
| Other Current Assets | $581,000 | $511,000 | $392,000 | $312,000 |
| Cash Cash Equivalents And Short Term Investments | $43,153,000 | $46,412,000 | $39,044,000 | $54,728,000 |
| Cash And Cash Equivalents | $1,754,000 | $3,620,000 | $4,555,000 | $54,728,000 |
| Other Non Current Assets | - | $31,000 | $31,000 | $54,000 |
| Prepaid Assets | - | - | - | $312,350 |
| Cash Financial | - | - | - | $54,727,740 |
| Debt | ||||
| Total Debt | $1,064,000 | $1,402,000 | $1,716,000 | $2,006,000 |
| Long Term Debt And Capital Lease Obligation | $700,000 | $1,064,000 | $1,402,000 | $1,715,000 |
| Current Debt And Capital Lease Obligation | $364,000 | $338,000 | $314,000 | $291,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,795,000 | $2,435,000 | $2,932,000 | $3,295,000 |
| Total Non Current Liabilities Net Minority Interest | $700,000 | $1,064,000 | $1,402,000 | $1,715,000 |
| Current Liabilities | $2,095,000 | $1,371,000 | $1,530,000 | $1,580,000 |
| Other Current Liabilities | $121,000 | $128,000 | $177,000 | $60,000 |
| Payables And Accrued Expenses | $1,006,000 | $427,000 | $648,000 | $704,000 |
| Payables | $1,006,000 | $427,000 | $648,000 | $560,000 |
| Accounts Payable | $1,006,000 | $427,000 | $648,000 | $560,000 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Total Equity Gross Minority Interest | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Stockholders Equity | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Retained Earnings | $-151,855,000 | $-130,036,000 | $-106,520,000 | $-81,851,000 |
| Other | ||||
| Ordinary Shares Number | $17,536,000 | $13,317,000 | $9,472,000 | $9,469,850 |
| Share Issued | $17,536,000 | $13,317,000 | $9,472,000 | $9,469,850 |
| Tangible Book Value | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Invested Capital | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Working Capital | $41,639,000 | $45,552,000 | $37,906,000 | $53,460,000 |
| Capital Lease Obligations | $1,064,000 | $1,402,000 | $1,716,000 | $2,006,000 |
| Total Capitalization | $42,159,000 | $46,200,000 | $38,729,000 | $54,404,000 |
| Additional Paid In Capital | $194,014,000 | $176,236,000 | $145,249,000 | $136,255,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $700,000 | $1,064,000 | $1,402,000 | $1,715,000 |
| Current Capital Lease Obligation | $364,000 | $338,000 | $314,000 | $291,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $604,000 | $478,000 | $391,000 | $525,000 |
| Net PPE | $1,189,000 | $1,681,000 | $2,194,000 | $2,605,000 |
| Accumulated Depreciation | $-1,257,000 | $-1,069,000 | $-849,000 | $-637,000 |
| Gross PPE | $2,446,000 | $2,750,000 | $3,043,000 | $3,242,000 |
| Other Properties | $1,573,000 | $1,895,000 | $2,197,000 | $2,510,000 |
| Machinery Furniture Equipment | $873,000 | $855,000 | $846,000 | $539,000 |
| Other Short Term Investments | $41,399,000 | $42,792,000 | $34,489,000 | $0 |
| Current Accrued Expenses | - | - | $118,000 | $144,000 |
| Leases | - | - | $213,000 | $193,000 |
| Properties | - | - | $0 | $0 |
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,875,000 | $-18,891,000 | $-15,734,000 | $-12,216,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,838,000 | $-18,858,000 | $-15,619,000 | $-11,848,000 |
| Cash Flow From Continuing Operating Activities | $-16,838,000 | $-18,858,000 | $-15,619,000 | $-11,848,000 |
| Operating Gains Losses | - | - | - | $-313,000 |
| Investing Activities | ||||
| Capital Expenditure | $-37,000 | $-33,000 | $-115,000 | $-368,000 |
| Investing Cash Flow | $1,335,000 | $-7,868,000 | $-34,554,000 | $-368,000 |
| Cash Flow From Continuing Investing Activities | $1,335,000 | $-7,868,000 | $-34,554,000 | $-368,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $13,591,000 | $25,791,000 | $0 | $57,362,000 |
| Financing Cash Flow | $13,637,000 | $25,791,000 | $0 | $57,607,000 |
| Cash Flow From Continuing Financing Activities | $13,637,000 | $25,791,000 | $0 | $57,607,000 |
| Net Common Stock Issuance | $13,591,000 | $25,791,000 | $0 | $57,362,000 |
| Common Stock Issuance | $13,591,000 | $25,791,000 | $0 | $57,362,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $1,754,000 | $3,620,000 | $4,555,000 | $54,728,000 |
| Beginning Cash Position | $3,620,000 | $4,555,000 | $54,728,000 | $9,337,000 |
| Changes In Cash | $-1,866,000 | $-935,000 | $-50,173,000 | $45,391,000 |
| Proceeds From Stock Option Exercised | $46,000 | $0 | $0 | $245,000 |
| Net Investment Purchase And Sale | $1,372,000 | $-7,835,000 | $-34,439,000 | $0 |
| Sale Of Investment | $56,939,000 | $48,685,000 | $13,688,000 | $0 |
| Purchase Of Investment | $-55,567,000 | $-56,520,000 | $-48,127,000 | $0 |
| Net PPE Purchase And Sale | $-37,000 | $-33,000 | $-115,000 | $-368,000 |
| Purchase Of PPE | $-37,000 | $-33,000 | $-115,000 | $-368,000 |
| Change In Working Capital | $290,000 | $-616,000 | $-420,000 | $-1,146,000 |
| Change In Other Current Liabilities | $-338,000 | $-314,000 | $-290,000 | - |
| Change In Payables And Accrued Expense | $698,000 | $-183,000 | $-73,000 | $-1,083,000 |
| Change In Prepaid Assets | $-70,000 | $-119,000 | $-57,000 | $-63,000 |
| Stock Based Compensation | $4,141,000 | $5,196,000 | $8,994,000 | $5,999,000 |
| Unrealized Gain Loss On Investment Securities | $22,000 | $-468,000 | $-49,000 | $0 |
| Depreciation Amortization Depletion | $528,000 | $546,000 | $525,000 | $453,000 |
| Depreciation And Amortization | $528,000 | $546,000 | $525,000 | $453,000 |
| Depreciation | $528,000 | $546,000 | $525,000 | $453,000 |
| Net Income From Continuing Operations | $-21,819,000 | $-23,516,000 | $-24,669,000 | $-16,528,000 |
| Change In Accrued Expense | - | $38,000 | $-161,000 | $-250,000 |
| Change In Payable | - | $-221,000 | $88,000 | $-833,000 |
| Change In Account Payable | - | $-221,000 | $88,000 | $-833,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Other Non Cash Items | - | - | $-290,000 | $-313,000 |
| Issuance Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |